If you have been reading about actin-binding fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-31. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
MHD oscillations are damped if the fluid is not perfectly conducting but has finite conductivity, or if viscous effects are present. MHD waves and oscillations are popular tools for the remote diagnostics of laboratory and astrophysical plasmas, for example, the Sun's corona (coronal seismology).
== Clinical significance == In vascular smooth muscle cell (VSMC), ADAMTS7 mediates VSMC migration, which plays an essential role during the development of atherosclerosis and restenosis. This proatherogenic effect has been demonstrated to specifically require the catalytic protease activity of ADAMTS7, as mice expressing a catalytically inactive mutant of the enzyme (E373Q) are similarly protected against atherosclerosis. Adamts7 deficiency in both the Ldlr−/– and Apoe−/– hyperlipidemic mouse models markedly attenuates formation of atherosclerotic lesions; furthermore, wire-injury experiments in the Adamts7−/– mouse show reduced neointima formation. The association of ADAMTS7 with atherosclerosis suggests that inhibition of ADAMTS7 should be atheroprotective in humans. A negative correlation between the expression levels of specific miRNAs and ADAMTS7 is observed in normal tissues but not in disease tissues, implying an altered miRNA-target interaction in the disease state. Accordingly, expression profiles of these miRNAs and ADAMTS7 may be useful diagnostic tools to differentiate cancer and lichen planus from normal tissues. ADAMTS7 has also been identified as a putative oncogene and reported to be mutated exclusively in Asians, which may have implications for the prevention and treatment of hepatocellular carcinoma. In addition, ADAMTS7 plays a crucial role in the pathogenesis of arthritis. For example, the FGF2/p65/miR-105/Runx2/ADAMTS axis is reportedly involved in osteoarthritis (OA) pathogenesis.
== History == The predecessor to the CAD, termed an evaporative electrical detector, was first described by Kaufman in 2002 at TSI Inc in US patent 6,568,245 and was based on the coupling of liquid chromatographic approaches to TSI's electrical aerosol measurement (EAM) technology. At around the same time Dixon and Peterson at California State University were investigating the coupling of liquid chromatography to an earlier version of TSI's EAM technology, which they called an aerosol charge detector. Subsequent collaboration between TSI and ESA Biosciences Inc. (now part of Thermo Fisher Scientific), led to the first commercial instrument, the Corona CAD, which received both the Pittsburgh Conference Silver Pittcon Editor's Award (2005) and R&D 100 award (2005). Continued research and engineering improvements in product design resulted in CADs with ever increasing capabilities. The newest iterations of the CAD are the Thermo Scientific Corona Veo Charged Aerosol Detector, Corona Veo RS Charged Aerosol Detector and Thermo Scientific Vanquish Charged Aerosol Detectors.
The European continent is home to a diverse spectrum of spontaneous and anthropogenic mummies. Some of the best-preserved mummies have come from bogs located across the region. The Capuchin monks that inhabited the area left behind hundreds of intentionally-preserved bodies that have provided insight into the customs and cultures of people from various eras. One of the oldest mummies (nicknamed Ötzi) was discovered on this continent. New mummies continue to be uncovered in Europe well into the 21st century.
Sources: en.wikipedia.org
==== Removal of N-terminal methionine ==== The initiating methionine (and, in bacteria, fMet) may be removed during translation of the nascent protein. For E. coli, fMet is efficiently removed if the second residue is small and uncharged, but not if the second residue is bulky and charged. In both prokaryotes and eukaryotes, the exposed N-terminal residue may determine the half-life of the protein according to the N-end rule.
9-Carboxymethoxymethylguanine (CMMG) is a compound which is known as the principal metabolite of the antiviral medication aciclovir (and its prodrug valaciclovir), and has been suggested as the causative agent in the neuropsychiatric side effects sometimes associated with these medications. These are mainly suffered by patients with kidney failure or otherwise decreased kidney function, and can include psychotic reactions, hallucinations, and rarely more complex disorders such as Cotard delusion. Patients suffering these symptoms following aciclovir treatment were found to have much higher levels of CMMG than normal, and since this is the first time Cotard delusion has been linked to a drug as a side effect, this discovery may be useful in the study of Cotard delusion and its treatment.
Miriam Luke. President, Henley Rowing Club and lately Chair, Henley Women's Regatta. For services to Women's Rowing. Martin Edward Machray. Executive Director of Performance, NHS England, London. For services to Healthcare. Malcolmina Mackay Macleod. Social and Health Carer. For services to the community of North Uist, Scotland. Professor Roma Maguire. Professor of Digital Health and Care, University of Strathclyde. For services to Health Care Research. Helen Ann Maitland. Lately National Director for Urgent and Unscheduled Care, Scottish Government. For services to NHS Scotland. Eric Malcomson. Founder and Chair, Tove Valley Broadband. For services to the community in the Tove Valley, Northamptonshire. Robert James Hammond Malcomson. Deputy Director, Cabinet Office. For public and voluntary service to the LGBTQ+ Community and to Homeless People. Sharon Manning. Cancer Nurse Specialist, Macmillan. For services to Cancer Patient Care. Deirdre Marshall. Team Leader, Ministry of Defence. For services to Defence. Kathryn Julia Marshall. Senior Manager, Lloyds Banking Group, Halifax. For services to Further Education and Skills. Robert James Martin. For services to Drama in Northern Ireland. Elsie Barbara Martlew. Lately Deputy Leader, City of Carlisle Council. For Political and Public Service. Paul Nicholas Martynenko. Vice-President, Registration and Standards, BCS, The Chartered Institute for IT. For services to the Information Technology Industry. Sarah Mason. Chief Executive Officer, Women's Aid Federation Northern Ireland. For services to Women and Girls.
Exothermic chemical reactions in closed systems do not change mass, but do become less massive once the heat of reaction is removed, though this mass change is too small to measure with standard equipment. In nuclear reactions, the fraction of mass that may be removed as light or heat, i.e. binding energy, is often a much larger fraction of the system mass. It may thus be measured directly as a mass difference between rest masses of reactants and (cooled) products. This is because nuclear forces are comparatively stronger than the Coulombic forces associated with the interactions between electrons and protons that generate heat in chemistry.
Another study of the PfSPZ vaccine was published in December 2022, reporting vaccine efficacy at up to 48% at 6 months follow up, and up to 46% efficacy at 18 months. Recent field studies have evaluated PfSPZ Vaccine in malaria-experienced African adults. A randomized, double-blind, placebo-controlled trial in Burkina Faso tested a three-dose intravenous regimen and reported vaccine efficacy of up to 48% at 6 months and 46% at 18 months against naturally acquired Plasmodium falciparum infection. The vaccine was well tolerated and immunogenic in this population. Additional studies in Equatorial Guinea examined multi-dose priming regimens of PfSPZ Vaccine followed by controlled human malaria infection (CHMI). Several schedules were found to be safe and capable of inducing significant protection against homologous challenge. By 2022 more than twenty clinical trials of PfSPZ-based products had been completed or were ongoing across Africa, Europe and the United States. PfSPZ Vaccine has also been evaluated in women of childbearing age and in participants who later became pregnant. Two randomized, double-blind, placebo-controlled trials in Mali investigated vaccination following presumptive antimalarial treatment. Across two transmission seasons, vaccine efficacy against Plasmodium falciparum parasitaemia in women of childbearing age ranged from 41% to 61%, depending on dose and year of follow-up. Among participants who conceived after vaccination, the vaccine was safe for mothers and infants and reduced the incidence of malaria parasitaemia during pregnancy.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.